Literature DB >> 10720912

Comparative study of brain lesions detected by magnetic resonance imaging between strabismus and nonstrabismus in infancy.

H Ohtsuki1, K Yoshifumi, S Hasebe, R Kono, Y Harada.   

Abstract

PURPOSE: To elucidate the causative factors in infantile esotropia, we evaluated morphological abnormalities in brain structures of esotropia patients showing any abnormal neurological signs in comparison to those of normal controls.
METHODS: Sixty-five developmentally normal children participated in this study. Of these 65, 38 demonstrated infantile esotropia and 27 were normal controls. All underwent magnetic resonance imaging (MRI) of the brain between 2 and 30 months.
RESULTS: Abnormal brain findings were noted in 3 (7. 9%) children in the strabismus group, whereas none of the children in the normal control group showed brain lesions. In these 3 cases, brain lesions involved periventricular leukomalacia, enlargement of the lateral ventricles with hypoplasia of the corpus callosum and myelination delay at the anterior horn adjacent to the lateral ventricles.
CONCLUSIONS: Brain lesions that may disturb normal maturation of the visuomotor system and eventually lead to strabismus could be found in some patients without any episode that would cause birth injury. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2000        PMID: 10720912     DOI: 10.1159/000027476

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  2 in total

1.  MR imaging of congenital or developmental neuropathic strabismus: common and uncommon findings.

Authors:  E Kim; J H Kim; J M Hwang; B S Choi; C Jung
Journal:  AJNR Am J Neuroradiol       Date:  2012-05-17       Impact factor: 3.825

2.  Voxel-based analysis of MRI detects abnormal visual cortex in children and adults with amblyopia.

Authors:  Janine D Mendola; Ian P Conner; Anjali Roy; Suk-Tak Chan; Terry L Schwartz; J Vernon Odom; Kenneth K Kwong
Journal:  Hum Brain Mapp       Date:  2005-06       Impact factor: 5.038

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.